Nirmatrelvir/ritonavir (Paxlovid) and COVID-19 recurrence ("Paxlovid rebound"): is the FAERS signal real?
Nirmatrelvir/ritonavir (Paxlovid) ↔ COVID-19 recurrence ("Paxlovid rebound")
Reporting over time (stimulated-reporting check)
No reporting spike: the pair's share of the drug's reports is fairly stable over time (busiest two years hold 78% of 20,089 reports), so stimulated reporting is unlikely to explain the signal.
Bars: reports per year as a share of all FAERS reports for this drug, 2004–2025; amber = spike year (>3× the median share, ≥50 reports). Source: openFDA count=receivedate, retrieved 2026-10-09.
"Paxlovid rebound" — recurrence of COVID-19 symptoms or a positive test 2–8 days after finishing a 5-day nirmatrelvir/ritonavir course, sometimes after testing negative in between — became widely enough recognized that CDC issued a Health Alert Network advisory about it in May 2022. The leading mechanistic explanation is that the drug's antiviral course may be short relative to the time needed to fully clear virus in some patients, allowing a viral (and symptomatic) rebound once the drug is stopped, rather than true reinfection. It is included here as a genuinely well-publicized, real, and mechanistically plausible phenomenon, though the precise frequency and whether it differs meaningfully from the "rebound" some untreated COVID-19 cases also show is still an active area of study.
Regulatory basis: CDC Health Alert Network Advisory 467 (May 24, 2022): rebound reported 2–8 days after recovery, median duration 3 days, not attributed to reinfection or resistance.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Defined 2–8 day post-course window |
| Strength | met | PRR 285.7 for "disease recurrence" |
| Consistency | met | Widely replicated; prompted an independent CDC advisory |
| Specificity | not established | The proposed mechanism isn't unique to this drug — likely reflects short antiviral-course length generally |
| Biological gradient | not established | Not clearly dose/duration related beyond the fixed 5-day course |
| Plausibility | met | Short antiviral course relative to viral clearance kinetics is a coherent, published hypothesis |
| Coherence | partial | Some rebound also occurs in untreated patients, complicating a clean causal story |
| Experiment | not established | No RCT designed specifically to test rebound causally |
| Analogy | met | Analogous to rebound phenomena described with other short-course antivirals |
This page's own qualitative read, not an automated/citation-gated assessment.
⚠ Trial evidence found, but doesn't capture rebound — EPIC-HR (NCT04960202), N=2,091
| Serious event | Nirmatrelvir/ritonavir (n=1,038) | Placebo (n=1,053) |
|---|---|---|
| COVID-19 (new/recurrent diagnosis) | 2 | 7 |
| COVID-19 pneumonia | 7 | 36 |
This is a genuine negative result for the specific rebound claim, not a confirmation. EPIC-HR, the pivotal registration trial, shows fewer COVID-19 and pneumonia events on drug than placebo, exactly as expected for an effective antiviral — it doesn't surface a rebound signal at all. That's consistent with the history: rebound was identified afterward, in real-world post-marketing use, not in this trial. It illustrates a real limit of trial AE tables: they can only surface what the trial was watching for, and nobody was specifically coding "symptom rebound 5–10 days after a negative test" as a term when EPIC-HR ran. View on ClinicalTrials.gov →